Last updated: February 21, 2026
What is NDC 00781-7122?
NDC 00781-7122 corresponds to Doxorubicin Hydrochloride Injection, a chemotherapy agent used primarily for malignancies such as breast cancer, ovarian cancer, and some hematological cancers. It is marketed in various formulations, typically as a sterile, preservative-free solution administered intravenously.
Market Overview
Doxorubicin remains a cornerstone in cancer treatment. Despite the availability of newer agents, its established efficacy sustains demand across multiple oncology indications. The drug’s global market was valued at approximately $500 million in 2022, with a compound annual growth rate (CAGR) of around 5% projected through 2027 [1].
Key Market Drivers:
- Increasing cancer incidence, especially breast and lung cancers.
- Expansion of combination therapies involving doxorubicin.
- Growth in global healthcare infrastructure, especially in emerging markets.
- Patent expiration and the rise of generic versions, lowering costs and expanding accessibility.
Competitive Landscape:
- Several approved generics: Teva, Sandoz, and Fresenius Kabi.
- Limited proprietary formulations from Innovators due to the age of the drug.
- Biosimilars or similar anthracycline agents in early development stages.
Regulatory Status
The drug is on the FDA's National Drug Code (NDC) directory as a generic. Patent exclusivity has expired, permitting multiple manufacturers. The supply chain mainly involves generic producers, with production standards governed by cGMP regulations.
Price Trends and Projections
Historical Pricing (United States)
| Year |
Average Wholesale Price (AWP) per 50mg vial |
Notes |
| 2018 |
$120 |
Stable rate |
| 2020 |
$125 |
Slight increase |
| 2022 |
$130 |
Ongoing affordability trend |
Current Pricing Dynamics
Retail prices for 50 mg vials have stabilized. However, hospital procurement prices can be 10-15% lower due to volume discounts. The entry of multiple generic manufacturers has exerted downward pressure on prices.
Future Price Projections (2023-2027)
| Year |
Expected AWP per 50mg vial |
Assumptions |
| 2023 |
$125-$130 |
Continued generic competition and market saturation |
| 2024 |
$122-$127 |
Slight decrease as biosimilar options emerge [2] |
| 2025 |
$120-$125 |
Further price stabilization, possible new biosimilar entry |
| 2026 |
$117-$122 |
Market saturation keeps prices low |
| 2027 |
$115-$120 |
No significant price increase, market remains competitive |
Key Market Factors Affecting Pricing
- Patent expiry catalyzed generic entry, leading to price declines.
- Global expansion could increase volume but may not substantially impact prices in mature markets.
- Potential new formulations or delivery methods could affect cost structure.
- Regulatory changes impacting import/export policies influence availability and pricing.
Distribution and Reimbursement
- Majority sold through hospital outpatient settings and specialty pharmacies.
- Reimbursement rates depend on government programs (Medicare, Medicaid) and private insurers, influencing net prices.
- Price negotiations, especially with large payers, tend to reduce list prices over time.
Risks and Opportunities
Risks:
- Market saturation limits further price declines.
- Emergence of biosimilars or alternative agents could erode market share.
- Regulatory delays or changes affecting drug approval or reimbursement.
Opportunities:
- Expanding indications, such as in combination therapies for new cancer types.
- Developing new formulations or delivery systems, justifying premium pricing.
- Entering emerging markets with unmet cancer treatment needs.
Conclusion
NDC 00781-7122 (Doxorubicin Hydrochloride Injection) faces a mature, highly competitive landscape. Pricing is unlikely to decline significantly beyond current levels unless new competing therapies or formulations emerge. Current projections suggest a slow, steady decline in average wholesale prices, stabilized through increased volume and generic competition.
Key Takeaways
- The drug's market value remains substantial due to its entrenched role in oncology.
- Prices have stabilized after patent expiration, with modest downward pressure expected.
- Market expansion, especially in emerging nations, offers growth opportunities.
- Biosimilar entry may accelerate price reductions over the next five years.
- Reimbursement policies significantly influence net prices.
FAQs
1. What factors most influence the price of doxorubicin injection?
Market competition, patent status, healthcare reimbursement policies, and manufacturing costs.
2. How will biosimilars impact doxorubicin prices?
Biosimilars can increase competition, potentially lowering prices by 10-20% over baseline.
3. Are there significant regional differences in pricing?
Yes. Prices tend to be higher in the U.S., with lower costs in Europe and emerging markets due to regulatory and market dynamics.
4. What future therapeutic developments could affect uptake?
Innovations like liposomal formulations or targeted drug delivery systems could shift demand away from traditional doxorubicin.
5. Is there potential for price increases due to supply chain disruptions?
Supply chain issues could temporarily elevate costs, but long-term prices are more dependent on market competition.
References
- MarketsandMarkets. (2022). Oncology Drugs Market by Type, Molecule Type, and Region – Global Forecast to 2027.
- IQVIA. (2023). National Sales Perspectives.
